Abeona Therapeutics Statistics
Total Valuation
ABEO has a market cap or net worth of $227.14 million. The enterprise value is $152.47 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, before market open.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABEO has 48.53 million shares outstanding. The number of shares has increased by 91.99% in one year.
| Current Share Class | 48.53M |
| Shares Outstanding | 48.53M |
| Shares Change (YoY) | +91.99% |
| Shares Change (QoQ) | +1.24% |
| Owned by Insiders (%) | 6.63% |
| Owned by Institutions (%) | 44.39% |
| Float | 34.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.85 |
| P/TBV Ratio | 5.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.08, with a Debt / Equity ratio of 0.52.
| Current Ratio | 6.08 |
| Quick Ratio | 5.99 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.26 |
Financial Efficiency
Return on equity (ROE) is -216.57% and return on invested capital (ROIC) is -91.93%.
| Return on Equity (ROE) | -216.57% |
| Return on Assets (ROA) | -46.41% |
| Return on Invested Capital (ROIC) | -91.93% |
| Return on Capital Employed (ROCE) | -69.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$758,738 |
| Employee Count | 136 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.38% in the last 52 weeks. The beta is 1.70, so ABEO's price volatility has been higher than the market average.
| Beta (5Y) | 1.70 |
| 52-Week Price Change | -39.38% |
| 50-Day Moving Average | 5.37 |
| 200-Day Moving Average | 5.54 |
| Relative Strength Index (RSI) | 36.32 |
| Average Volume (20 Days) | 541,895 |
Short Selling Information
The latest short interest is 2.39 million, so 4.92% of the outstanding shares have been sold short.
| Short Interest | 2.39M |
| Short Previous Month | 2.52M |
| Short % of Shares Out | 4.92% |
| Short % of Float | 6.98% |
| Short Ratio (days to cover) | 7.19 |
Income Statement
| Revenue | n/a |
| Gross Profit | -34.36M |
| Operating Income | -64.21M |
| Pretax Income | -76.66M |
| Net Income | -63.73M |
| EBITDA | -62.21M |
| EBIT | -64.21M |
| Earnings Per Share (EPS) | -$1.55 |
Full Income StatementBalance Sheet
The company has $97.72 million in cash and $23.05 million in debt, giving a net cash position of $74.67 million or $1.54 per share.
| Cash & Cash Equivalents | 97.72M |
| Total Debt | 23.05M |
| Net Cash | 74.67M |
| Net Cash Per Share | $1.54 |
| Equity (Book Value) | 44.03M |
| Book Value Per Share | 0.96 |
| Working Capital | 84.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$56.02 million and capital expenditures -$2.45 million, giving a free cash flow of -$58.46 million.
| Operating Cash Flow | -56.02M |
| Capital Expenditures | -2.45M |
| Free Cash Flow | -58.46M |
| FCF Per Share | -$1.20 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |